L3VLUP
ProSign in

AXGN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AXGNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AXGN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterAXGNVRTX
Q3 20201 holders, $13m31 holders, $21.9bn
Q4 20201 holders, $21m30 holders, $18.4bn
Q1 20212 holders, $36m31 holders, $15.4bn
Q2 20212 holders, $52m30 holders, $12.7bn
Q3 20212 holders, $36m35 holders, $10.1bn
Q4 20211 holders, $2.4m28 holders, $12.4bn
Q1 20221 holders, $4k23 holders, $16.1bn
Q2 20222 holders, $17m25 holders, $18.1bn
Q3 20221 holders, $26m22 holders, $18.4bn
Q4 20221 holders, $18m28 holders, $18.4bn
Q1 2023none listed holders, n.a.26 holders, $21.4bn
Q2 2023none listed holders, n.a.27 holders, $24.7bn
Q3 2023none listed holders, n.a.33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 2024none listed holders, n.a.31 holders, $29.8bn
Q2 2024none listed holders, n.a.29 holders, $33.4bn
Q3 2024none listed holders, n.a.27 holders, $33.5bn
Q4 2024none listed holders, n.a.26 holders, $28.5bn
Q1 2025none listed holders, n.a.21 holders, $35.4bn
Q2 20251 holders, $1.9m21 holders, $32.3bn
Q3 20251 holders, $7.7m22 holders, $25.9bn
Q4 20251 holders, $13m26 holders, $31.8bn
Q1 20263 holders, $66m25 holders, $31.8bn
Q2 20262 holders, $41m26 holders, $34.6bn
AXGN

Axogen Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$35.4bn
Buyers
10
Sellers
11

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 21 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only AXGN (0)

None.

Only VRTX (21)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Capital Research Global Investors, Capital World Investors, Element Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →